BRAF mutations in ovarian cancer: immune microenvironment and therapeutic advances.

Ovarian cancer is a highly lethal malignancy of the female reproductive system, characterized by a poor prognosis and complex therapeutic challenges influenced by various molecular and microenvironmental factors. Among these, mutations in the BRAF gene have received increasing attention across multiple malignancies due to their involvement in oncogenic signaling pathways and implications for targeted therapy. Concurrently, the tumor immune microenvironment has been recognized as a critical determinant in the initiation and progression of tumors. This review explores the impact of BRAF mutations on the immune microenvironment in ovarian cancer, summarizes recent advances in the field, and assesses the potential clinical significance of these findings in informing therapeutic strategies. Clinical trial number: Not applicable.